Scagliotti G V, Piani M, Gatti E, Gozzelino F, Albera C, Pozzi E
University of Turin, Pulmonary Diseases Department, S. Luigi Gonzaga Hospital, Torino, Italy.
Eur Respir J. 1989 Sep;2(8):746-50.
Pretreatment serum neuron specific enolase (NSE) and plasma bombesin/gastrin releasing peptide (BN/GRP) were measured in 92 lung cancer patients and 17 controls. The mean level of NSE (p less than 0.001) and BN/GRP (p less than 0.05) was significantly raised in patients with small cell lung cancer (SCLC, n = 62) compared to non-SCLC (n = 30) and controls. The mean concentration of NSE in extensive SCLC was significantly greater (p less than 0.005) than in limited stage but with a substantial overlap of values. Forty-seven out of 62 SCLC patients had at least one of the two markers raised (sensitivity 76%, specificity 83%), 44 had raised NSE (sensitivity 71%, specificity 89%) but only 24 had BN/GRP raised (sensitivity 42%, specificity 91%). At restaging, 16 of 19 patients with SCLC responsive to chemotherapy showed a significant fall of NSE; on the other hand, BN/GRP fell significantly in only 3 patients, remaining unchanged in the majority of responding patients. In conclusion, the combined determination of NSE and BN/GRP in SCLC, at diagnosis and during the follow-up, was not found to be superior to NSE determination alone.
对92例肺癌患者和17例对照者测定了治疗前血清神经元特异性烯醇化酶（NSE）和血浆蛙皮素/胃泌素释放肽（BN/GRP）。与非小细胞肺癌（n = 30）和对照者相比，小细胞肺癌（SCLC，n = 62）患者的NSE平均水平（p < 0.001）和BN/GRP平均水平（p < 0.05）显著升高。广泛期小细胞肺癌患者的NSE平均浓度显著高于局限期（p < 0.005），但数值有大量重叠。62例小细胞肺癌患者中有47例至少有两种标志物之一升高（敏感性76%，特异性83%），44例NSE升高（敏感性71%，特异性89%），但只有24例BN/GRP升高（敏感性42%，特异性91%）。在重新分期时，19例对化疗有反应的小细胞肺癌患者中有16例NSE显著下降；另一方面，只有3例患者的BN/GRP显著下降，大多数有反应的患者保持不变。总之，在小细胞肺癌的诊断和随访过程中，联合测定NSE和BN/GRP并不优于单独测定NSE。
